Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several
angiogenesis-driven eye diseases including diabetic macular edema and the neovascular …

The treatment of ocular neovascular diseases is being revolutionized by intravitreal
therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for …

PURPOSE: To determine the serum concentrations of bevacizumab and vascular
endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who …

Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins,
which are used to treat a wide number of diseases (eg, oncology, inflammation and …

Intravitreal administration is the method of choice in drug delivery to the retina and/or
choroid. Rabbit is the most commonly used animal species in intravitreal pharmacokinetics …

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has
become the standard treatment for Age-Related Macular Degeneration; however, the …

Purpose: Monthly dosing with inhibitors of vascular endothelial growth factor (VEGF) results
in stable or improved visual acuity in most patients with neovascular age-related macular …

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is a
commonly used therapy for numerous retinal diseases. The most commonly used of these …

purpose. To investigate the pharmacokinetics of bevacizumab in rabbits for three different
routes of administrations: intravitreal injection, subconjunctival injection, and eye drops …

The aims of this research were to (1) create a curated universal database of intravitreal
volumes of distribution (V ss, ivt) and clearances (CL ivt) of small molecular weight …